RxSight (RXST) has a profit margin of -43.8%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
RxSight (RXST) currently reports a profit margin of -43.8% as of September 2026. That compares with -25.15% in the prior-year period — down 74.2% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore RxSight's profit margin history and peer comparisons.
RxSight's profit margin decreased from -25.15% to -43.8% — a 74.2% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
RxSight's profit margin of -43.8% is lower than the Healthcare sector average of 17.63%. That is roughly 348.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but RxSight's current -43.8% should be judged against Healthcare norms (sector average: 17.63%) and against RXST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -43.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for RxSight, and consider following RXST for alerts when major investors trade the stock.